Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. - Wikidata - wikimedia - TriplyDB

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

http://www.wikidata.org/entity/Q34296827

about

Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease New Features about Tau Function and Dysfunction Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies Diverse molecular targets for therapeutic strategies in Alzheimer's disease Therapeutic and diagnostic challenges for frontotemporal dementia The role of tau in neurodegenerative diseases and its potential as a therapeutic target GSK-3 as potential target for therapeutic intervention in cancer A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β Nutritional and Pharmacological Strategies to Regulate Microglial Polarization in Cognitive Aging and Alzheimer's Disease.Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies Advances in recent patent and clinical trial drug development for Alzheimer's disease.GSK3β Interactions with Amyloid Genes: An Autopsy Verification and Extension GSK3β inhibition protects the immature brain from hypoxic-ischaemic insult via reduced STAT3 signalling.Glycogen synthase kinase-3: a potential preventive target for prostate cancer management The importance of tau phosphorylation for neurodegenerative diseases A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.Activation of muscarinic receptors inhibits glutamate-induced GSK-3β overactivation in PC12 cells.Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.Tau-based therapeutic approaches for Alzheimer's disease - a mini-review.GSK-3β, a pivotal kinase in Alzheimer disease.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors.Promotion of natural tooth repair by small molecule GSK3 antagonists.Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.Pharmacophore feature-based virtual screening for finding potent GSK-3 inhibitors using molecular docking and dynamics simulations.The allosteric glycogen synthase kinase-3 inhibitor NP12 limits myocardial remodeling and promotes angiogenesis in an acute myocardial infarction model.Restoration of Megalin-Mediated Clearance of Alveolar Protein as a Novel Therapeutic Approach for Acute Lung Injury.Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases.An Overview on the Clinical Development of Tau-Based Therapeutics.Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus

P2860

Q21131229-1D03A3D6-7ABC-4043-8787-912AC96E5305 Q26739412-0570DDDE-9943-4929-95D4-2EF9DD19900C Q26750922-6CADFB1D-636F-4217-999F-7875AD95AFE6 Q26768475-11327101-C09D-4D7E-95BE-44EC7A3E2E5A Q26769957-47944787-2AEC-4856-8648-618E25BBA31B Q26827193-8189273C-2139-4F53-AD92-04F70C1A8895 Q26998919-AD9E8B05-7F15-4017-81E9-AFB349907ACD Q27005032-FA0D213E-A47F-40EB-B6A2-57F526595B4C Q27013811-CF27F0B1-D397-4F79-A39B-8FCFF8FFB544 Q28550557-304E4231-3962-4D81-877B-1E9396A79551 Q33770234-3400A894-03DD-49F4-B6DB-1B2881D9C708 Q33887379-3DEB24F7-4213-4DBC-8508-EEE38D7D912B Q34014237-438D3E6F-07E4-4121-AF1A-A74A383D550F Q34408888-CAB46FA6-4B21-4E90-8BBA-41A741BAE8F1 Q34974167-3057F2F2-9D0B-4DBB-AC67-6B531597D969 Q35738142-57F1060C-8FB0-43F8-8226-43F83D1688D6 Q36224340-782C131D-D7BA-4BE4-9D61-B1A763EE3114 Q36378223-9EAAA5B4-49CD-40B6-882E-232BAEB252B6 Q36580561-E623885D-A0DF-4560-8F54-2A97553021FA Q36968220-20A1364E-15F1-4C38-B051-05C530EA66A5 Q37075360-E534993E-0BA9-451E-B95E-2B12A5CB4261 Q37728532-221BAE71-7A5C-4FB0-B1A7-24FED9E8BDBE Q37739881-08DE47F6-D0AD-4DEE-BD4F-9D96DE09A160 Q38126701-233AA962-4F29-4E77-B1DB-33A26764E9F2 Q38204620-C6E4960E-54F7-4470-8B78-98101A94E055 Q38218085-997ACDBD-EAB4-40A9-9C36-1F34D342B848 Q38272835-F01E9339-F790-4BBF-B6CC-A4DABE6ED402 Q38699013-601D7666-C8F7-4886-80FE-27A59A9ADFCE Q39008696-BAAD0647-3BB7-4FB4-A3E8-1518DADFC1FB Q39032328-9F3C1FBA-00EF-4F9C-AF0D-024AA9DF8DE1 Q39067484-668A9241-5D17-4959-9935-C510334A2134 Q41891305-4AD937D4-BD75-4415-95D5-D113643DB258 Q47598692-AED1B971-B2E0-4CEB-8B60-287FA6EAFCAD Q47842866-BC25BF04-64A8-4726-92AB-8CDA379459C4 Q48146413-9419F99D-AF97-4E9A-A2A9-6BCCC5D6F6DB Q52594209-B71589BE-CA4B-4A7D-9B8D-77E9061B8E11 Q58712518-F7F63D98-DCA4-423D-8161-D8AD30E25184

P2860

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

http://www.wikidata.org/entity/Q34296827

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

@ast

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

@en

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

@nl

type

label

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

@ast

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

@en

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

@nl

prefLabel

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

@ast

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

@en

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.

@nl

P1433

Q34296827-D8410467-10B3-4B13-8335-C5BF394BEEE3

P1476

Q34296827-7D4C46F1-6F98-46E6-BE15-35ACF0B43BA7

P2093

Q34296827-11C58EE5-D59D-4F93-AEFC-FFDAE2224767

Q34296827-1435E4D3-ACE1-4772-932F-4B07C74013AD

Q34296827-545AAB57-DAB6-4807-8C4A-569BDD516B6D

Q34296827-7C981C4F-6B05-4F7A-9768-70078A7BCA15

Q34296827-A0D41A80-07E3-404F-9DB0-44F764909B1B

Q34296827-A5603A3D-7FDD-4428-8EEA-43C44232F0C9

Q34296827-BBD45296-5240-4554-BB2D-E407C5BDD6E4

Q34296827-D23799A4-2782-47A2-A1BA-63B3F2048B83

P304

Q34296827-68AE5B5F-CDC1-48DD-B383-0BFDA1BCF8F4

P31

Q34296827-D6F50125-38B5-4B5B-B021-ECC450C3B44B

P356

Q34296827-A5B0B9B3-5F96-412B-BB5C-00B9A4B33F08

P433

Q34296827-71284BD8-C8DB-46D7-8BED-E1864BF7671C

P478

Q34296827-89D29C90-11B9-41CC-9FC1-1AD2DF9E09E1

P50

Q34296827-4D625488-7CBE-4099-9802-48131FE5CCC1

Q34296827-4EAA4E53-9F88-4AD1-8DA9-3DA220C1E55E

P577

Q34296827-149F04C9-2D62-409C-A04E-7F6EAFAD792A

P698

Q34296827-E3177879-6F00-4B84-8A86-20F0F0A6EFB1

P921

Q34296827-92C1730F-4308-4423-8E4E-870B69160CCF

P356

JAD-2012-120805

P1433

Journal of Alzheimer's Disease

P1476

Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study

@en

P2093

Belén Gómez-Carrillo

http://www.w3.org/2001/XMLSchema#string

David Fleet

http://www.w3.org/2001/XMLSchema#string

Hermann J Gertz

http://www.w3.org/2001/XMLSchema#string

Joan A Vericat

http://www.w3.org/2001/XMLSchema#string

Klaus C Steinwachs

http://www.w3.org/2001/XMLSchema#string

María V Andrés

http://www.w3.org/2001/XMLSchema#string

Pilar Redondo

http://www.w3.org/2001/XMLSchema#string

Teresa León

http://www.w3.org/2001/XMLSchema#string

P304

205-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JAD-2012-120805

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Teodoro Del Ser

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22936007

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease